{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:50:58Z","timestamp":1784019058907,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p> Tumor mutational burden (TMB) is one of the most significant predictive biomarkers of immunotherapy efficacy in non-small cell lung cancer (NSCLC). Radiomics allows high-throughput extraction and analysis of advanced and quantitative medical imaging features. This study develops and validates a radiomic model for predicting TMB level and the response to immunotherapy based on CT features in NSCLC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p> Pre-operative chest CT images of 127 patients with NSCLC were retrospectively studied. The 3D-Slicer software was used to outline the region of interest and extract features from the CT images. Radiomics prediction model was constructed by LASSO and multiple logistic regression in a training dataset. The model was validated by receiver operating characteristic (ROC) curves and calibration curves using external datasets. Decision curve analysis was used to assess the value of the model for clinical application.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1037 radiomic features were extracted from the CT images of NSCLC patients from TCGA. LASSO regression selected three radiomics features (Flatness, Autocorrelation and Minimum), which were associated with TMB level in NSCLC. A TMB prediction model consisting of 3 radiomic features was constructed by multiple logistic regression. The area under the curve (AUC) value in the TCGA training dataset was 0.816 (95% CI: 0.7109\u20130.9203) for predicting TMB level in NSCLC. The AUC value in external validation dataset I was 0.775 (95% CI: 0.5528\u20130.9972) for predicting TMB level in NSCLC, and the AUC value in external validation dataset II was 0.762 (95% CI: 0.5669\u20130.9569) for predicting the efficacy of immunotherapy in NSCLC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The model based on CT radiomic features helps to achieve cost effective improvement in TMB classification and precise immunotherapy treatment of NSCLC patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-024-01221-8","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:02:39Z","timestamp":1708012959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiexiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfu","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongtao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"issue":"1","key":"1221_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"10299","key":"1221_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"issue":"10","key":"1221_CR3","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","volume":"28","author":"MB Schabath","year":"2019","unstructured":"Schabath MB, Cote ML. Cancer Progress and priorities: lung Cancer. Cancer Epidemiol Biomark Prev. 2019;28(10):1563\u201379.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1221_CR4","doi-asserted-by":"publisher","first-page":"n2363","DOI":"10.1136\/bmj.n2363","volume":"375","author":"M Miller","year":"2021","unstructured":"Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. Bmj. 2021;375:n2363.","journal-title":"Bmj"},{"key":"1221_CR5","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","volume":"157","author":"EN Imyanitov","year":"2021","unstructured":"Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"1221_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung Cancer. J Clin Oncol. 2022;40(6):586\u201397.","journal-title":"J Clin Oncol"},{"issue":"10027","key":"1221_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet"},{"issue":"10183","key":"1221_CR8","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"25","key":"1221_CR9","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al. First-line Nivolumab in stage IV or recurrent non-small-cell lung Cancer. N Engl J Med. 2017;376(25):2415\u201326.","journal-title":"N Engl J Med"},{"issue":"12","key":"1221_CR10","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808\u201325.","journal-title":"Cancer Discov"},{"issue":"1","key":"1221_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356.","journal-title":"Ann Oncol"},{"issue":"3","key":"1221_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jtho.2020.11.021","volume":"16","author":"D Pan","year":"2021","unstructured":"Pan D, Hu AY, Antonia SJ, Li CY. A gene mutation signature predicting immunotherapy benefits in patients with NSCLC. J Thorac Oncol. 2021;16(3):419\u201327.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"1221_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1470-2045(18)30434-0","volume":"19","author":"K Gourd","year":"2018","unstructured":"Gourd K. 2018 ASCO annual meeting. Lancet Oncol. 2018;19(7):865\u20136.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1221_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/1078-0432.CCR-21-2649","volume":"28","author":"N Gavrielatou","year":"2022","unstructured":"Gavrielatou N, Liu Y, Vathiotis I, Zugazagoitia J, Aung TN, Shafi S, Fernandez A, Schalper K, Psyrri A, Rimm DL. Association of PD-1\/PD-L1 co-location with immunotherapy outcomes in non-small cell lung Cancer. Clin Cancer Res. 2022;28(2):360\u20137.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1221_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung Cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(7):633\u201341.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1221_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40425-019-0647-4","volume":"7","author":"L Fancello","year":"2019","unstructured":"Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019;7(1):183.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1221_CR17","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","volume":"11","author":"H Yu","year":"2016","unstructured":"Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in lung Cancer. J Thorac Oncol. 2016;11(7):964\u201375.","journal-title":"J Thorac Oncol"},{"key":"1221_CR18","doi-asserted-by":"publisher","first-page":"105643","DOI":"10.1016\/j.phrs.2021.105643","volume":"169","author":"F Cucchiara","year":"2021","unstructured":"Cucchiara F, Petrini I, Romei C, Crucitta S, Lucchesi M, Valleggi S, Scavone C, Capuano A, De Liperi A, Chella A, et al. Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. Pharmacol Res. 2021;169:105643.","journal-title":"Pharmacol Res"},{"key":"1221_CR19","doi-asserted-by":"publisher","first-page":"620246","DOI":"10.3389\/fonc.2021.620246","volume":"11","author":"Q Wen","year":"2021","unstructured":"Wen Q, Yang Z, Dai H, Feng A, Li Q. Radiomics study for predicting the expression of PD-L1 and tumor mutation burden in non-small cell lung Cancer based on CT images and Clinicopathological features. Front Oncol. 2021;11:620246.","journal-title":"Front Oncol"},{"key":"1221_CR20","doi-asserted-by":"crossref","unstructured":"He B, Dong D, She Y, Zhou C, Fang M, Zhu Y, Zhang H, Huang Z, Jiang T, Tian J, et al. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-000550"},{"issue":"6","key":"1221_CR21","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s10278-013-9622-7","volume":"26","author":"K Clark","year":"2013","unstructured":"Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, et al. The Cancer imaging archive (TCIA): maintaining and operating a public information repository. J Digit Imaging. 2013;26(6):1045\u201357.","journal-title":"J Digit Imaging"},{"issue":"2","key":"1221_CR22","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cell.2018.03.059","volume":"173","author":"A Blum","year":"2018","unstructured":"Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530.","journal-title":"Cell"},{"issue":"5","key":"1221_CR23","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.chest.2016.03.001","volume":"149","author":"GZ Cheng","year":"2016","unstructured":"Cheng GZ, San Jose Estepar R, Folch E, Onieva J, Gangadharan S, Majid A. Three-dimensional printing and 3D slicer: powerful tools in understanding and treating structural lung disease. Chest. 2016;149(5):1136\u201342.","journal-title":"Chest"},{"issue":"3","key":"1221_CR24","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Liti\u00e8re S, Dancey J, Chen A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352.","journal-title":"Lancet Oncol"},{"issue":"26","key":"1221_CR25","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1038\/s41388-021-01853-y","volume":"40","author":"J Wu","year":"2021","unstructured":"Wu J, Li L, Zhang H, Zhao Y, Zhang H, Wu S, Xu B. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. Oncogene. 2021;40(26):4413\u201324.","journal-title":"Oncogene"},{"issue":"12","key":"1221_CR26","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","volume":"17","author":"M Mino-Kenudson","year":"2022","unstructured":"Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, et al. Predictive biomarkers for immunotherapy in lung Cancer: perspective from the International Association for the Study of Lung Cancer pathology committee. J Thorac Oncol. 2022;17(12):1335\u201354.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1221_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","volume":"18","author":"F Zhou","year":"2021","unstructured":"Zhou F, Qiao M, Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol. 2021;18(2):279\u201393.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"1221_CR28","doi-asserted-by":"publisher","first-page":"670","DOI":"10.21037\/tlcr-22-244","volume":"11","author":"BX He","year":"2022","unstructured":"He BX, Zhong YF, Zhu YB, Deng JJ, Fang MJ, She YL, Wang TT, Yang Y, Sun XW, Belluomini L, et al. Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk. Transl Lung Cancer Res. 2022;11(4):670\u201385.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"1221_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.21037\/tlcr-23-171","volume":"12","author":"J Yang","year":"2023","unstructured":"Yang J, Shi W, Yang Z, Yu H, Wang M, Wei Y, Wen J, Zheng W, Zhang P, Zhao W, et al. Establishing a predictive model for tumor mutation burden status based on CT radiomics and clinical features of non-small cell lung cancer patients. Transl Lung Cancer Res. 2023;12(4):808\u201323.","journal-title":"Transl Lung Cancer Res"},{"issue":"22","key":"1221_CR30","doi-asserted-by":"publisher","first-page":"20864","DOI":"10.1002\/cam4.6665","volume":"12","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Tao X, Yuan P, Zhang Z, Ying J, Guo L, Li N, Wang S, Li J, Liu Y, et al. Predictive value of (18) F-FDG PET\/CT and serum tumor markers for tumor mutational burden in patients with non-small cell lung cancer. Cancer Med. 2023;12(22):20864\u201377.","journal-title":"Cancer Med"},{"key":"1221_CR31","doi-asserted-by":"crossref","unstructured":"Yin W, Wang W, Zou C, Li M, Chen H, Meng F, Dong G, Wang J, Yu Q, Sun M, et al. Predicting tumor mutation burden and EGFR mutation using clinical and Radiomic features in patients with malignant pulmonary nodules. J Pers Med. 2022;13(1).","DOI":"10.3390\/jpm13010016"},{"issue":"10","key":"1221_CR32","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/1759-7714.13163","volume":"10","author":"X Wang","year":"2019","unstructured":"Wang X, Kong C, Xu W, Yang S, Shi D, Zhang J, Du M, Wang S, Bai Y, Zhang T, et al. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature. Thorac Cancer. 2019;10(10):1904\u201312.","journal-title":"Thorac Cancer"},{"issue":"2","key":"1221_CR33","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s00259-020-04955-z","volume":"48","author":"SE Dahlsgaard-Wallenius","year":"2021","unstructured":"Dahlsgaard-Wallenius SE, Hildebrandt MG, Johansen A, Vilstrup MH, Petersen H, Gerke O, H\u00f8ilund-Carlsen PF, Morsing A, Andersen TL. Hybrid PET\/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review. Eur J Nucl Med Mol Imaging. 2021;48(2):584\u201391.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-024-01221-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-024-01221-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-024-01221-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:05:40Z","timestamp":1708013140000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-024-01221-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1186\/s12880-024-01221-8","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"assertion":[{"value":"11 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Hefei Cancer Hospital, Chinese Academy of Sciences (Approved number: SL-KY2023\u2013080) and was conducted in accordance with the regulations of the Ethics Committee of Hefei Cancer Hospital, Chinese Academy of Sciences. Informed consent was obtained from all recruited patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}